CLSN : Summary for Celsion Corporation - Yahoo Finance

U.S. Markets closed

Celsion Corporation (CLSN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.29-0.01 (-3.99%)
At close: 4:00PM EDT

0.29 0.00 (1.22%)
After hours: 5:09PM EDT

People also watch
DCTHCPRXCYCCTHLDAVEO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.30
Open0.29
Bid0.29 x 500
Ask0.29 x 2900
Day's Range0.28 - 0.29
52 Week Range0.19 - 1.78
Volume923,542
Avg. Volume2,839,601
Market Cap15.75M
Beta1.41
PE Ratio (TTM)-0.34
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
    Capital Cubeyesterday

    Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017

    Categories: Yahoo Finance Get free summary analysis Celsion Corp. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Celsion Corp. – Threshold Pharmaceuticals, Inc., ArQule, Inc., ImmunoGen, Inc., Endocyte, Inc., Spectrum Pharmaceuticals, Inc., ZIOPHARM Oncology, Inc., Exelixis, Inc. and Keryx Biopharmaceuticals, Inc. (THLD-US, ARQL-US, IMGN-US, ECYT-US, SPPI-US, ... Read more (Read more...)

  • GlobeNewswire14 days ago

    Celsion Corporation Reports Year End 2016 Financial Results and Provides Business Update

    LAWRENCEVILLE, N.J., March 16, 2017-- Celsion Corporation, an oncology drug development company, today announced financial results for the year ended December 31, 2016 and provided an update on its development ...

  • Forget Gilead, Buy These Small-Cap Biotech Stocks Instead
    Zacks15 days ago

    Forget Gilead, Buy These Small-Cap Biotech Stocks Instead

    At this juncture, we advise investors to forget Gilead (GILD), a Zacks Rank #4 (Sell) stock, and invest in some other small cap biotech stocks (market capitalization below $200 million) that carry an impressive Zacks Rank.